Objective: To determine if human growth hormone (hGH) replacement therapy alters pharmacokinetics of hydrocortisone (CS) substitution in hypopituitary adults. Design: To this aim, we analysed serum and salivary CS profiles 270 min after oral CS administration at baseline and 6 and 12 months after initiation of hGH replacement therapy. Methods: Serum IGF-I, cortisol-binding globulin (CBG), thyroxine-binding globulin (TBG) and sex hormone-binding hormone (SHBG) were measured using commercially available radioimmunoassays. In-house immunofluorometric assays were employed for measurements of CS and hGH. Results: hGH replacement did not change total serum CS bioavailability (area under the serum cortisol profile curve). Interference of orally administered CS with salivary measurement of free CS (fCS) caused significant bias. Therefore, fCS levels were calculated from their total CS and cortisolbinding globulin (CBG) levels. CBG decreased by approximately 30 % after both 6 and 12 months of hGH replacement therapy …n ˆ 20; P, 0:01†. A significant negative correlation between DCBG …CBG6months 2 CBGbaseline † and DIGF-I …IGF ÿ I6months 2 IGF ÿ Ibaseline † was observed …P ˆ 0:04†: The calculated values of free CS tended to increase with physiological hGH replacement, but this effec
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.